Low doses of recombinant human erythropoietin raise serum interleukin-2 levels in hemodialysis patients

Journal of Nephrology

Volumn 9, Issue 1, 1996, Pages 30-34

  Mysliwska, Jolanta ^a   Bryl, Ewa ^a   Szołkiewicz, Marek ^a   Manitius, Jacek ^a   Mysliwski, Andrzej ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

erythropoietin; hemodialysis patients; interleukin 2

Indexed keywords

INTERLEUKIN 2; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029882138     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Revillard JP. Immunological alterations in chronic renal insufficiency. Adv Nephrol 1979; 8: 365-82.
2. Sennesael JJ, Van der Niepen P, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121-8.
3. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer KH. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int 1986; 29: 1209-14.
4. Raska K, Raskova J, Shea SM, Frankel RM, Wood RH. T cell subsets and cellular immunity in end-stage renal disease. Am J Med 1983; 75: 734-40.
5. Lotze MT. Interleukin-2. In: Aggarwal BB, Gutterman JU, eds. Human cytokines. Boston, Oxford, London: Blackwell Scientific Publications, 1992; 81-96.
6. Beaurain B, Naret C, Marcon L, et al. In vivo T cell preactivation in chronic uremic hemodialyzed and non-hemodialyzed patients. Kidney Int 1989; 36: 636-44.
7. Chatenoud L, Dugas B, Beaurain G, et al. Presence of preactivated T cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci USA 1986; 83: 7457-61.
8. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumour necrosis factor. Kidney Int 1990; 37: 116-25.
9. Andrew OT, Schoenfeld PY, Hopewell PC, Hunphreys MH. Tuberculosis in patients with end-stage renal disease. Am J Med 1980; 68: 59-65.
10. Lindner A, Farewell VT, Sherrard DJ. High incidence of neoplasia in uremic patients receiving long-term dialysis. Nephron 1981; 27: 292-6.
11. Sethi D, Brown EA, Gower PE. CAPD, protective against developing dialysis-associated amyloid? Nephron 1988; 50: 85-6.
12. Debska-Slizien A, Kabata J, Rutkowski B, Ciesielski D, Jankowska E, Manitius A. Effects of recombinant human erythropoietin (r-Hu EPO) administration on erythropoiesis in dialysis patients. Pol Arch Med Wew 1991; 86: 341-50.
13. Paczek L, Schaefer RM, Heidland A. Improved function of B lymphocytes in dialysis patients treated by recombinant human erythropoietin. Schaefer RM, Heidland A, Horl WH, eds. Erythropoietin in the 90s. Contrib Nephrol. Basel: Karger, 1990 vol 98: 36-41.
14. Imiela J, Korczak-Kowalska G, Malecki R, Nowaczyk M, Stepien-Sopniewska B, Górski A. Immunomodulatory action of human recombinant erythropoietin in man. Immunol Let 1993; 35: 271-6.
15. Grimm PC, Sinai-Trieman L, Sekiya NM, et al. Effect of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990; 38: 12-8.
16. Walz G, Kunzendorf U, Josimovic-Alasevic O, et al. Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentrations in end-stage renal failure. Nephron 1990; 56: 157-61.
17. Barany P, Fehrman I, Godoy C. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 1992; 37: 90-6.
18. Buemi M, Allegra A, Alosi C, Fristina N. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects. Am J Nephrol 1991; 11: 281-3.
19. Kang XX, Hirano T, Oka K, et al. Recovery of decreased ability of peripheral-blood mononuclear cells from chronic renal failure to produce interleukin-1 and β after renal transplantation. Nephron 1991; 58: 450-5.
20. Fung MR, Greene WC. The human interleukin-2 receptor: insight into subunit structure and growth signal transduction. Seminars in Immunology 1990; 2: 119-28.
21. Huang YP, Pechere JC, Michel M, et al. In vivol cell activation, in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women. J Immunol 1992; 148 (3): 715-21.
22. Spina CA, Fahey JH, Durkos-Smith D, Dorey F, Sarna G. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy. J Biol Response Mod 1983; 3, 2: 458.
23. Talmadge JE, Herberman RB, Chirigos MA, et al. Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators including recombinant interferons and interleukin 2. J Immunol 1985; 135, 4: 2483.